FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Clinical trials for FALLOPIAN TUBE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Measles virus reprogrammed to attack ovarian cancer shows promise in early trial
Disease control OngoingThis study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 02:22 UTC
-
New drug combo could slow ovarian Cancer's return
Disease control OngoingThis study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 17, 2026 02:18 UTC
-
New drug combo shows promise for returning ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, olaparib and cediranib, in 70 people with ovarian, peritoneal, or fallopian tube cancer that had returned after initial treatment. The goal was to see if the drugs could slow or stop tumor growth by blocking enzymes cancer cells need …
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug duo shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for recurrent ovarian cancer: drug combo extends life?
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…
Matched conditions: FALLOPIAN TUBE SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC